Germany Acne Therapeutics Market Analysis

Germany Acne Therapeutics Market Executive Analysis

The Germany acne therapeutics market size is at around $367 Mn in 2022 and is projected to reach $538 Mn in 2030, exhibiting a CAGR of 4.9% during the forecast period. In 2020, Germany's current health expenditure was paid for by transfers and subsidies from the government. According to the Federal Statistical Office (Destatis), this represents a rise of $17.37 Bn, or 31.5%, from the previous year. As a consequence, 15.7% of the $460.07 Bn in current health expenditure was made up of government transfers and subsidies, an increase of 3.0 % in age points from the previous year. In the world, the German healthcare system dates back to the 1880s, making it one of the oldest. The public and private health insurance sectors make up the system's two main organizational groups. The idea of solidarity serves as the foundation for the public health care system in Germany. No matter their financial situation, everyone who is covered by a public health insurer receives the same level of medical treatment. This is accomplished with the help of an income-based common fund to which everyone pays.

Acne vulgaris is a chronic skin disease that is most common in adolescents. Relapse and recovery periods are frequent and can last even into adulthood. Acne vulgaris is a significant financial burden and has a significant effect on a patient's quality of life in terms of their health. The most prevalent type of acne, acne vulgaris, was the eighth most prevalent illness worldwide in 2010. Acne inversa, tropical acne, acne mechanica, excoriated acne, acne aestivalis, acne cosmetic, acne rosacea, acne neonatorum, industrial acne, drug-induced acne, acne necrotica, hyperandrogenic acne, and acne necrotica are additional types of acne. Germany has a greater reported prevalence of acne, with 26.8% of the 896 participants. According to reports, acne peaks between the ages of 14 and 29. Rural and non-Westernized nations have reduced rates of acne prevalence.

Topical medications (such as retinoids, benzoyl peroxide [BPO], azelaic acid, antibiotics, and dapsone) and/or systemic medications can be used to treat acne vulgaris (antibiotics, zinc, antiandrogens, and isotretinoin). In randomized, controlled clinical trials conducted in Germany, daily parallel application of adapalene and nadifloxacin was also found to be effective and well tolerated in patients with acne vulgaris. In order to maximize effectiveness and boost patient compliance, current therapeutic advancements for acne concentrate on set combinations of substances with complementary effects. These include topical clindamycin and benzoyl peroxide, an approach that also slows the spread of Propionibacterium acnes-resistant strains, and the fixed combination of retinoids with antimicrobials, specifically a clindamycin phosphate 1.2%/tretinoin 0.025% and an adapalene 0.1%/benzoyl peroxide 2.5% gel. Topical dapsone 5% or triethyl citrate and ethyl linoleate are two novel treatment options that have been studied in clinical studies.

Market Dynamics

Market Growth Drivers

In Germany, a sizable portion of the population suffers from acne, a common skin condition. The Germany acne therapeutics market is anticipated to rise as more people turn to treatment for their acne. People are more likely to seek treatment for acne as a way to enhance their appearance and boost their confidence as the significance of skincare is becoming more widely recognized. Effective acne remedies are now in greater demand as a result of this.

Market Restraints

Alternative acne therapies like over-the-counter medicines or natural cures may be preferred by some patients. This might reduce the need for prescribed acne treatments. Some acne treatments may have unpleasant side effects, which may reduce patient adherence and happiness. This may lead to a decline in the Germany acne therapeutics market.

Competitive Landscape

Key Players

• Adragos Pharma (DEU)
• Vifor Pharma Deutschland (DEU)
• Pharmainitiative Bayern (DEU)
• Pharall (DEU)
• Oranis (DEU)
• Teva Pharmaceuticals
• L'Oréal
• Sun Pharmaceuticals
• Johnson & Johnson
• Abbvie

Healthcare Policies and Regulatory Landscape

A federal higher body under the Federal Ministry of Health's purview is the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). Section 2 of the German Medicinal Products Act (Arzneimittelgesetz, AMG) specifies the legal meaning of a medicinal product. The goal of this legislation is to guarantee the security of pharmaceuticals. Therefore, homeopathic medicinal products require a German or European registration, whereas finished medicinal products as specified by the AMG may only be marketed after receiving the appropriate German or European marketing authorization.

The BfArM's primary duties include the registration of pharmaceuticals as well as the marketing authorization of those goods. After a medication has been given marketing authorization, the BfArM's responsibilities do not stop. The results regarding a medicinal product's safety are incomplete at the time of first licensure. As a result, following the granting of the marketing authorization, experiences relating to the use of a medicinal product must also be gathered and assessed sequentially and systematically. This is the pharmacovigilance division's most significant duty. This division will coordinate the required steps to avert the risk if the evaluation of the drug risks indicates that the licensing status of a medicinal product needs to be adjusted to the current state of knowledge in science.